1254782-72-3

Upstream product

• 100-01-6 4-nitro-aniline 
• 90918-78-8 N-methyl-N-(4-nitrophenyl)propionamide 
• 4850-93-5 N-(4-nitrophenyl)propionamide 
• 814-68-6 acryloyl chloride 
• 112077-95-9 N-(4-aminophenyl)-N-methylpropionamide 

Relevant academic research and scientific papers

Discovery of selective irreversible inhibitors for EGFR-T790M

Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer. A series of novel covalent EGFR kinase inhibitors with selectivity for the clinically relevant T790M 'gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening. A representative compound 3i was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.

EGFR INHIBITORS AND METHODS OF TREATING DISORDERS

The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.